FDA Approves IncobotulinumtoxinA for Excessive Drooling in Adult Patients
July 5th 2018Officials with the FDA have approved the supplemental Biologics License Application (sBLA) for incobotulinumtoxinA (Xeomin, Merz North America) for the treatment of chronic sialorrhea, a common symptom in patients with neurological disorders.
Read More
Immunotherapy Combo Treatment Improves Progression-Free Survival in Triple-Negative Breast Cancer
July 3rd 2018Atezolizumab (Tecentriq, Roche) plus chemotherapy nab-paclitaxel (Abraxane) met its co-primary endpoint of progression-free survival in patients with metastatic triple-negative breast cancer.
Read More